MANUEL PAZ

MANUEL PAZ

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
DKDima Kabbani
Dima Kabbani
EOEfrat Orenbuch-Harroch
Efrat Orenbuch-Harroch
Carl BoodmanCarl Boodman
Carl Boodman
SBSarah Broad
Sarah Broad
MPMANUEL PAZ
MANUEL PAZ
KDKaren Doucette
Karen Doucette
Bartonella quintana infection is rarely described to be transmitted through solid organ transplant (SOT). We report a cluster of using donor-derived B quintana infection and the attack rate from Bartonella seropositive donors. In this retrospective study of SOT recipients that received an organ from an unhoused deceased donor (UDD) in Alberta in 2022-2023, serology testing for Bartonella was performed indirect immunofluorescent assay on UDDs and recipients of UDDs with positive serology. Titers ≥1:64 were considered positive. During the study period, 31/32 UDDs were tested for immunoglobulin G to Bartonella (20 negative, 11 positive for B quintana and/or B henselae). Thirty-two organs were transplanted from the 11 seropositive donors. Six SOT recipients developed bartonellosis secondary to B quintana (4 SOT recipients received organs from 3 seropositive donors, and 2 SOT recipients from 1 UDD with no stored sample for testing). The attack rate for clinical disease from positive donors was 12.5% (4/32). The main presentation was skin nodules/papules (median 5.5 months) with bacillary angiomatosis in 4/6. Bartonella serology was positive in 5/6 SOT recipients (initially negative in 2) and blood B quintana quantitative polymerase chain reaction in 1. None had visceral involvement. All donors had history of substance use. This outbreak of bartonellosis reinforces the potential for unexpected donor-transmitted infections. Clinicians should be aware of high transmission of B quintana through transplant from infected UDDs.

28 December 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
MPMANUEL PAZ
MANUEL PAZ
MPMagaly Padilla
Magaly Padilla
EPEduardo Perez-Alba
Eduardo Perez-Alba
JSJessica Sauceda
Jessica Sauceda
ACAdrián Camacho-Ortiz
Adrián Camacho-Ortiz
Vaccine-associated rubella is a very rare adverse effect after rubella vaccination; we report the characteristics of a young women who, after a vaccination campaign where she received three different vaccines against influenza, tetanus/diphtheria, and measles/rubella, developed a fever and rash consistent with rubella disease that was confirmed by sequencing of the virus. The evolution was favorable. The woman had two close contacts who did not develop the disease. Follow-up of the patient and her contacts was important to detect complications and for epidemiology surveillance.

13 June 2026 in Future Microbiology
Verified
Journal Article
Closed access
MPMANUEL PAZ
MANUEL PAZ
KCKarla Paola Cuellar-Calderón
Karla Paola Cuellar-Calderón
SFSamantha Flores-Treviño
Samantha Flores-Treviño
JAJoel Isaí Alcala-González
Joel Isaí Alcala-González
MRMaría Teresa Ramírez-Elizondo
María Teresa Ramírez-Elizondo
ACAdrián Camacho-Ortiz
Adrián Camacho-Ortiz
Mycobacterium colombiense is a seldom reported non-tuberculous mycobacteria causing infections mostly in immunosuppressed patients. Thus, we present the findings of three M. colombiense isolation cases from a third-level hospital in Monterrey, Mexico, during 2020-2024. Mycobacterial identification was performed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and Anyplex™ MTB/NTM Real-time Detection. Patients were people living with Human Immunodeficiency Virus (PLHIV), with pneumonia and lymphadenopathy. Patients had high HIV viral loads and low CD4 counts (21-103 cells/mm3). None of the cases had specific Mycobacterium avium complex (MAC) treatment, and all of them showed clinical improvement. Current non-tuberculous mycobacteria discrimination tests may not effectively diagnose significant pathogens like M. colombiense, potentially leading to delays in treatment and negatively impacting patient outcomes.